Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 14.2%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares rose 14.2% during mid-day trading on Wednesday . The stock traded as high as $3.81 and last traded at $3.77, approximately 1,995,400 shares changed hands during trading. An increase of 54% from the average daily volume of 1,297,427 shares. The stock had previously closed at $3.30.

LXRX has been the topic of several recent analyst reports. G.Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Wedbush reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday. Finally, Citigroup downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $3.00 to $4.00 in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.45.

The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01. The firm has a market capitalization of $400.65 million, a PE ratio of -3.31 and a beta of 1.00. The company’s fifty day simple moving average is $3.63 and its 200-day simple moving average is $3.88.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The company’s revenue was up 4124.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.26) earnings per share. Analysts forecast that Lexicon Pharmaceuticals, Inc. will post 0.93 earnings per share for the current year.

In other Lexicon Pharmaceuticals news, CEO Lonnel Coats purchased 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average cost of $3.13 per share, with a total value of $156,500.00. Following the completion of the purchase, the chief executive officer now owns 127,639 shares in the company, valued at approximately $399,510.07. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Over the last three months, insiders bought 178,749 shares of company stock worth $474,560. Insiders own 6.40% of the company’s stock.

Several large investors have recently bought and sold shares of LXRX. Quantitative Systematic Strategies LLC lifted its stake in shares of Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 8,302 shares in the last quarter. Wedbush Securities Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 33.0% in the second quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock worth $1,222,000 after buying an additional 48,182 shares in the last quarter. Swiss National Bank lifted its stake in shares of Lexicon Pharmaceuticals by 18.3% in the second quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 13,700 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Lexicon Pharmaceuticals by 217.5% in the second quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock worth $548,000 after buying an additional 59,685 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter worth about $92,000. 96.27% of the stock is currently owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Profit Margin

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit